DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Bumetanide (Bumetanide) - Indications and Dosage



Bumetanide injection is indicated for the treatment of edema associated with congestive heart failure, hepatic and renal disease, including the nephrotic syndrome.

Almost equal diuretic response occurs after oral and parenteral administration of bumetanide. Therefore, if impaired gastrointestinal absorption is suspected or oral administration is not practical, bumetanide should be given by the intramuscular or intravenous route.

Successful treatment with bumetanide following instances of allergic reactions to furosemide suggests a lack of cross-sensitivity.


Dosage should be individualized with careful monitoring of patient response.

Parenteral Administration:  
Bumetanide injection may be administered parenterally (IV or IM) to patients in whom gastrointestinal absorption may be impaired or in whom oral administration is not practical.

Parenteral treatment should be terminated and oral treatment instituted as soon as possible.

The usual initial dose is 0.5 mg to 1 mg intravenously or intramuscularly. Intravenous administration should be given over a period of 1 to 2 minutes. If the response to an initial dose is deemed insufficient, a second or third dose may be given at intervals of 2 to 3 hours, but should not exceed a daily dosage of 10 mg.

Miscibility and Parenteral Solutions:
The compatibility tests of bumetanide injection with 5% Dextrose Injection, 0.9% Sodium Chloride Injection, and Lactated Ringer’s Injection in both glass and plasticized PVC (Viaflex) containers have shown no significant absorption effect with either containers, nor a measurable loss of potency due to degradation of the drug. However, solutions should be freshly prepared and used within 24 hours.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.


Bumetanide Injection, USP is available as:








1 mg/4 mL

4 mL

Box of 10


Multi-dose Vial

0.25 mg/mL

10 mL

Box of 10

Created: October, 2007

Store at 20 to 25°C (68 to 77°F). [See USP controlled room temperature.]

PROTECT FROM LIGHT. Retain in carton until ready to use.

Do not use the injection if it is discolored or contains a precipitate.

Printed in USA                                                                       EN-1632

Manufactured by Hospira, Inc., Lake Forest, IL 60045 USA

Novation and NOVAPLUS® are trademarks of Novation, LLC.

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017